Pharma company,
Granules India touched a near-record high on Friday after the company bagged the US Food & Drug Administration (USFDA) approval for Penicillamine Capsules USP, 250 mg. As much as 2.5% gain was recorded in Granules stock on Sensex in early deals.
At around 1.49 pm, Granules was trading at Rs422.95 per piece up 0.83% on Sensex. The stock has touched an intraday high of Rs430 per piece which is near the all-time high of Rs438 per piece.
Penicillamine Capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Penicillamine would be manufactured at Granules manufacturing facility in Chantilly, Virginia and is expected to be launched shortly.
Granules now have a total of 35 ANDA approvals from US FDA (33 Final approvals and 2 tentative approvals).
In another development on Friday, Granules Share Transfer and Stakeholders Relationship Committee of the Board approved to allot 34,000 equity shares consequent to exercise of stock options under ESOS 2009.